For intramuscular testosterone replacement therapy, which laboratory tests and clinical evaluations should be performed and how often?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 1, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Monitoring for Intramuscular Testosterone Replacement Therapy

For men on IM testosterone, monitor testosterone levels at 3-6 months then annually, hematocrit at 3-6 months then annually, and PSA/digital rectal exam at 3-12 months then annually (for men ≥40 years), with immediate urologic referral if PSA rises >1.4 ng/mL in 12 months or exceeds 4.0 ng/mL at any time. 1

Initial Baseline Testing (Before Starting Therapy)

Before initiating IM testosterone, obtain:

  • Testosterone level (morning, fasting)
  • Hematocrit or hemoglobin
  • PSA level (for men ≥40 years)
  • Digital rectal examination (for men ≥40 years)
  • Voiding history (standardized questionnaire)
  • Sleep apnea screening 2, 1

Critical contraindication: Do not start therapy if baseline hematocrit >48% (or >50% at high altitude), PSA >4.0 ng/mL, or abnormal digital rectal exam 1

Early Follow-Up (First Year)

At 3-6 Months After Initiation:

Testosterone level monitoring:

  • For IM testosterone enanthate or cypionate: Measure serum testosterone midway between injections 1
  • Target: Mid-normal range (approximately 400-600 ng/dL)
  • If mid-interval testosterone >600 ng/dL or <350 ng/dL, adjust dose or frequency 1

Hematocrit: Check at 3-6 months 1, 3

  • Stop therapy immediately if hematocrit >54% until it decreases to safe levels
  • Evaluate for hypoxia and sleep apnea before restarting at reduced dose 1

PSA and prostate monitoring (for men ≥40 years):

  • Check PSA at 3-12 months 1
  • Perform digital rectal examination 1

Clinical assessment:

  • Symptom response to treatment
  • Adverse effects evaluation
  • Urinary symptoms (LUTS)
  • Sleep apnea symptoms
  • Gynecomastia 2, 1

Repeat Testing Every 3-6 Months During First Year:

Continue monitoring testosterone, hematocrit, and PSA every 3-6 months throughout the first year 2

Long-Term Monitoring (After First Year)

Annual Testing:

Required for all patients:

  • Testosterone level (midway between injections for IM preparations) 1
  • Hematocrit 1, 3
  • Clinical symptom assessment 1

For men ≥40 years (or younger if high-risk):

  • PSA level 1
  • Digital rectal examination 1

Critical Safety Thresholds Requiring Immediate Action

Obtain Urologic Consultation If:

  1. PSA increase >1.4 ng/mL within any 12-month period 1

    • This threshold is based on the 90% confidence limit for PSA variability and is more sensitive than older recommendations 2, 1

  2. Confirmed PSA >4.0 ng/mL at any time 1

  3. Any abnormality on digital rectal examination 1

  4. Substantial worsening of lower urinary tract symptoms 1

Alternative PSA Monitoring Approach (More Conservative):

If PSA increases by 0.7-0.9 ng/mL in one year, repeat PSA in 3-6 months and perform biopsy if any further increase 2

Hematocrit Management:

  • Stop therapy if hematocrit >54% 1
  • Evaluate for secondary causes (hypoxia, sleep apnea)
  • Restart only after hematocrit normalizes, using reduced dose 1

Timing of Blood Draws for IM Testosterone

This is critical for accurate interpretation:

  • For testosterone enanthate or cypionate: Draw blood midway between injections 1
  • Document the specific ester, dose, concentration, injection interval, and timing of last injection with every lab draw 4
  • Without this context, testosterone results are meaningless and can lead to inappropriate dose adjustments 4

Common Pitfalls to Avoid

  1. Don't automatically use every-2-week dosing - Weekly or more frequent dosing may provide more stable levels and fewer peak-trough symptoms 4, 5

  2. Don't ignore timing of blood draws - Random testosterone levels without knowing injection timing cannot guide therapy 4

  3. Don't dismiss modest PSA rises - The threshold of >1.4 ng/mL in 12 months is clinically significant, not the older 2.0 ng/mL threshold 1

  4. Don't continue therapy with hematocrit >54% - This is an absolute indication to stop until levels normalize 1

  5. Don't skip prostate monitoring in men ≥40 - Testosterone therapy increases PSA by average 0.3-0.44 ng/mL, making surveillance essential 1

Special Considerations

For men with osteoporosis: Measure bone mineral density of lumbar spine and/or femoral neck after 1-2 years of therapy 1

Liver function tests: Not routinely needed for IM testosterone (only required for oral preparations) 2

Age-specific prostate monitoring: Guidelines specifically recommend prostate monitoring for men 40-69 years at increased risk and men 55-69 years who choose monitoring 1

References

1
Guideline

testosterone therapy in men with hypogonadism: an endocrine society clinical practice guideline.

The Journal of clinical endocrinology and metabolism, 2018

Related Questions

Is a weekly 0.7 mL injection of testosterone (200 mg/mL) appropriate for a 55‑year‑old male construction worker with normal baseline labs?
In a 75-year-old man receiving testosterone replacement therapy (200 mg testosterone enanthate every two weeks) with free testosterone 203 pg/mL, total testosterone 889 ng/dL, and estradiol 43 pg/mL, what further workup and treatment adjustments are recommended?
In a young male with low serum testosterone (7.1 nmol/L) and symptoms of decreased libido and fatigue, what intramuscular testosterone replacement regimen should be used?
How are low testosterone levels defined and what are the recommended treatment options?
How should a 50-year-old man with a serum testosterone of 245 ng/dL be evaluated and managed?
What is the appropriate antimicrobial and supportive therapy for a patient with heel wound necrosis?
What is the appropriate dose, contraindications, monitoring, adverse effects, and alternatives for finifibrate in an adult patient?
Which medical specialties should a female patient with a foot ulcer, possibly diabetic and elderly with multiple comorbidities, be evaluated by?
What is the appropriate treatment for an 89-year-old patient with an acute gout flare in the wrist, serum uric acid approximately 9 mg/dL, and an estimated glomerular filtration rate of 41 mL/min?
Can you provide a concise summary of the cardiac catheterization findings, highlighting the abnormal results?
In a 60-year-old patient with progressive muscle spasms, limb rigidity, paresthesia, normal electrolyte panel, spasms that improve with baclofen, worsening of symptoms when lying still and attempting to sleep, requiring straight leg positioning at night, and no weakness, what is the most likely diagnosis and recommended management?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.